Interleukin-2 Receptor Antibody Reduces Rejection Rates and Graft Loss in Live-Donor Kidney Transplant Recipients
Lim WH, Chang SH, Chadban SJ, Campbell SB, Dent H, Russ GR, McDonald SP. Transplantation. 2009 Nov 27;88(10):1208-13
This registry analysis found that compared to no antibody therapy, living-donor recipients who received IL-2 receptor antibody treatment at the
time of transplant were at lower risk for acute rejection. At 5 years, IL-2 receptor antibody was also associated with a lower risk of overall graft failure at 5 years, and better renal function at 1 year, although not at 3 years.
Related Articles:
- Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
- Influence of Renal Function on the Effects of Early Revascularization in Non-ST-Elevation Myocardial Infarction
- Subclinical Rejection in Stable Positive Crossmatch Kidney Transplant Patients: Incidence and Correlations
Recent Comments